A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience

CONCLUSIONS: Optimizing use of current therapies, as well as identifying and advancing novel therapeutic modalities such as eculizumab, are vital for the improvement of AMR prevention and treatment in LTRs to extend long-term allograft function and survival.PMID:37994573 | DOI:10.1177/10600280231213112
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research